Gold prices steady, holding sharp gains in wake of soft U.S. jobs data
Anixa Biosciences Inc (NASDAQ:ANIX) Director Arnold M. Baskies reported purchasing 5,000 shares of common stock on July 18, 2025. The shares were bought at a price of $3.39, totaling $16,950. The purchase comes as ANIX shares have shown strong momentum, delivering a 22% return over the past six months. According to InvestingPro data, analysts have set price targets ranging from $7 to $10, suggesting significant upside potential from current levels.
With a market capitalization of ~$111 million, Anixa Biosciences maintains strong liquidity, with InvestingPro analysis showing the company holds more cash than debt. Following the transaction, Baskies directly owns 125,000 shares of Anixa Biosciences Inc.
In other recent news, Anixa Biosciences has announced significant developments concerning its ovarian cancer initiatives. The United States Patent and Trademark Office is set to issue a new patent for Anixa’s ovarian cancer vaccine technology, which targets the anti-Müllerian hormone receptor, type II (AMHR2). This patent, held by Cleveland Clinic with exclusive worldwide rights licensed to Anixa, covers methods for eliciting an immune response against AMHR2. Additionally, Anixa Biosciences has dosed the first patient in the fourth cohort of its Phase 1 clinical trial for a CAR-T therapy targeting recurrent ovarian cancer. This trial, in partnership with Moffitt Cancer Center, is designed to evaluate safety and potential efficacy, with no dose-limiting toxicities observed in previous cohorts. Furthermore, H.C. Wainwright has maintained its Buy rating and $7.00 price target for Anixa Biosciences, following the completion of enrollment in a Phase 1 trial for its breast cancer vaccine. Preliminary data from this trial, funded by the U.S. Department of Defense, show promising immune responses in over 70% of patients. These developments highlight Anixa’s ongoing efforts in cancer vaccine and therapy innovation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.